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Introduction
Vitamin K-antagonists, also known as oral anticoagulants (OAC), are widely used for the treatment and prophylaxis of thromboembolic diseases 1 . Short-term OACtreatment is often applied after deep venous thrombosis whereas long-term treatment may be required for atrial fibrillation or after prosthetic heart valve implantation. In the Netherlands alone, some 270.000 people (1.7% if of the total population) receive longterm OAC-treatment. Vitamin K is an essential micronutrient that serves as a cofactor for the transformation of selective glutamic acid (Glu) residues into -carboxyglutamic acid (Gla) during the biosynthesis of the so-called Gla-proteins including the vitamin Kdependent coagulation factors 2 . In all known Gla-proteins the Gla residues are essential for the function of these proteins. OAC are used to block the -carboxylation of the vitamin K-dependent coagulation factors (II, VII, IX and X), and three anticoagulant proteins (C, S, and Z); OAC treatment leads to dysfunctional, undercarboxylated species also known as PIVKAs. OAC treatment also affects the synthesis and function of a number of other Gla proteins including the non-coagulation protein matrix Gla-protein (MGP) in cartilage and the vasculature. The first reports suggesting extra-hepatic effects of vitamin K antagonists were published in the nineteen seventies, when it was found that women receiving OAC treatment between the 6 th and 12 th week of pregnancy gave birth to children with severe bone abnormalities (chondrodysplasia punctata). Presently, it is commonly agreed that the most plausible mechanism underlying this phenomenon is incomplete -carboxylation of MGP, resulting in excessive cartilage calcification and subsequent nasal and distal digital hypoplasia, and epiphyseal stippling 3, 4 .
Recent publications have demonstrated that cardiovascular calcifications are the result of an actively regulated process [5] [6] [7] [8] 
Materials and methods:
Forty five aortic valves were obtained after routine cardiac replacement surgery.
The specimens came from 26 women and 19 men (mean age: 71 years; Table 1) Histopathologic inspection of the samples showed typical aspects with partial or total valve destructions induced by basophilic-amorphous calcified deposits. Calcification was visualized by von Kossa staining. The calcified area was measured using a microscope coupled to a computized morphometry system (quantimed 570, Leica, the Netherlands).
Five sections (20 µm apart) were used for morphometric analysis, and the calcification area was expressed as a percentage of the total section area. All morphometric measurements were conducted by two independent persons. The Medical Ethics
Committee of the University of Tuebingen approved the study protocol and all subjects gave their written informed consent.
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Results and discussion
A more than two-fold difference was observed between the marcoumar-treated and non-treated groups, with a mean calcified area of 16% in the non-treated group and 37% in the OAC-treated group (Figure 1) . The difference was statistically significant at p<0.02 using the Wilcoxon signed-ranks test. A possible explanation for these observations is that marcoumar treatment results in a decreased protection against tissue calcification due to the impairment of MGP, thus leading to more pronounced valvular calcification. Even low dose OAC treatment combined with a relative short period of treatment (like in this study) resulted in significantly more calcification. Many patients, however, receive OAC life-long with INR values well above the range indicated in our study cohort. Since coumarin derivatives are widely used, physicians should be aware of this potential adverse effect on the vasculature.
